Volume 17, Number 8—August 2011
Letter
Seroepidemiology of Saffold Cardiovirus Type 2
Table
SAFV-neutralizing antibodies in blood samples from humans of different ages and from different geographic regions*
Country | No. samples | Patient age† | Years collected | No. (%) samples |
||||
---|---|---|---|---|---|---|---|---|
SAFV-2 pos‡ | SAFV-3 pos‡ | SAFV pos§ | SAFV-2 pos + SAFV-3 neg | SAFV-2 neg + SAFV-3 pos | ||||
Netherlands | 29 | 9 mo | 2006–2007 | 15 (52) | 4 (14) | 15 (52) | 11 | 0 |
Netherlands | 26 | 24 mo | 2006–2007 | 21 (81) | 20 (77) | 25 (96) | 5 | 4 |
Netherlands | 30 | 18–39 y | 2004 | 30 (100) | 29 (97) | 30 (100) | 1 | 0 |
Finland | 30 | 2–2.5 y | 1997–1998 | 10 (33) | 21 (70) | 24 (80) | 3 | 14 |
Cameroon | 29 | 5–15 y | 1997 | 28 (97) | 28 (97) | 29 (100) | 1 | 1 |
Indonesia | 30 | 4–40 y | 1997–1998 | 30 (100) | 30 (100) | 30 (100) | 0 | 0 |
*SAFV, Saffold virus; pos, positive; neg, negative.
†Samples were collected from patients at this age or within this age range.
‡Titer >15.
§Cumulative positive for antibodies against SAFV-2 and/or SAFV-3.